13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001782539
Total reported value
$131.5M
$131.5M
45 檔
37.7%
The Q1 2024 SEC filing reveals that Nan Fung Group Holdings Ltd held a total portfolio value of $131.5M, covering 45 public equity positions.
During Q1 2024, Nan Fung Group Holdings Ltd's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ILMN | Illumina Inc | Stock-Healthcare | 15.17% | — | — | |
| 2 | HRMY | Harmony Biosciences Holdings | Stock-Other | 11.47% | +0.13% | — | |
| 3 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 9.69% | — | — | |
| 4 | OCS | Oculis Holding AG | Stock-Other | 4.87% | -4.52% | -15.91% | |
| 5 | LAB | Standard Biotools Inc | Stock-Other | 4.73% | — | — | |
| 6 | EXAIEUR | Exscientia PLC | Stock-Other | 4.56% | — | — | |
| 7 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.26% | — | — | |
| 8 | GERN | Geron CORP | Stock-Other | 4.05% | — | +44.99% | |
| 9 | INCY | Incyte CORP | Stock-Healthcare | 3.91% | +0.46% | +131.16% | |
| 10 | ✓ | Merus N V | Stock-Other | 3.73% | — | -34.68% | |
| 11 | ONC | Beone Medicines Ltd-adr | Stock-Other | 3.34% | -0.44% | +91.50% | |
| 12 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 2.41% | — | -27.94% | |
| 13 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 2.37% | — | — | |
| 14 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.24% | — | — | |
| 15 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.97% | +0.63% | +22.59% | |
| 16 | ASND | Ascendis Pharma A/S | Stock-Other | 1.90% | -2.57% | EXIT | |
| 17 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.76% | +0.09% | +243.46% | |
| 18 | REPL | Replimune Group Inc | Stock-Other | 1.55% | — | +10.93% | |
| 19 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 1.51% | — | — | |
| 20 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 1.42% | -0.01% | — | |
| 21 | EXEL | Exelixis Inc | Stock-Healthcare | 1.41% | — | — | |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.41% | -0.13% | +380.71% | |
| 23 | ✓ | Stock-Other | 1.31% | — | — | ||
| 24 | PACB | Pacific Biosciences Of Calif | Stock-Other | 0.95% | — | — | |
| 25 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.88% | — | +199.17% | |
| 26 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.81% | — | — | |
| 27 | CABA | Cabaletta Bio Inc | Stock-Other | 0.75% | — | — | |
| 28 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.64% | -0.24% | — | |
| 29 | BMEA | Biomea Fusion Inc | Stock-Other | 0.55% | — | — | |
| 30 | ✓ | Athira Pharma Inc | Stock-Other | 0.46% | — | — | |
| 31 | TRML | Tourmaline Bio Inc | Stock-Other | 0.45% | — | — | |
| 32 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.43% | — | — | |
| 33 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.41% | — | — | |
| 34 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.41% | +0.57% | — | |
| 35 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 0.34% | — | — | |
| 36 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.32% | — | — | |
| 37 | ✓ | Stock-Other | 0.26% | — | — | ||
| 38 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.22% | +1.20% | — | |
| 39 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.21% | — | +307.08% | |
| 40 | ✓ | Affimed N V | Stock-Other | 0.18% | — | — | |
| 41 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.17% | — | +106.46% | |
| 42 | KOD | Kodiak Sciences Inc | Stock-Other | 0.16% | — | +62.68% | |
| 43 | ✓ | Immatics NV | Stock-Other | 0.15% | — | — | |
| 44 | FGENEUR | Fibrogen Inc | Stock-Other | 0.14% | — | — | |
| 45 | GRTX | Galera Therapeutics Inc | Stock-Other | 0.08% | — | — |
According to official SEC Form 13F filings, Nan Fung Group Holdings Ltd reported a total U.S. public equity portfolio value of $131.5M across 45 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ILMN, HRMY, NVLSEUR) accounted for 37.7% of total reported equity market value during Q1 2024.
During Q1 2024, Nan Fung Group Holdings Ltd's top holdings by market value included ILMN (15.2%)、HRMY (11.5%)、NVLSEUR (9.7%). The largest single position, ILMN, represented 15.2% of total portfolio value.
In Q1 2024, Nan Fung Group Holdings Ltd made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.